228 related articles for article (PubMed ID: 19117204)
1. Antibody response for L1, E6, E7 HPV 16, and HPV 18 antigens in Tunisian women with cervical cancer.
Achour M; Zeghal D; Kochbati L; Kahla S; Zouari F; Maâlej M; Oueslati R
J Immunoassay Immunochem; 2009; 30(1):82-96. PubMed ID: 19117204
[TBL] [Abstract][Full Text] [Related]
2. Antibody response for L1, E6 and E7 HPV 16 and HPV 18 antigens in Tunisian women with cervical cancer and controls.
Achour M; Zeghal D; Kochbati L; Kahla S; Zouari F; Maalej M; Oueslati R
J Immunoassay Immunochem; 2008; 29(3):266-80. PubMed ID: 18569375
[TBL] [Abstract][Full Text] [Related]
3. Analysis of antibody response to HPV 16 and HPV 18 antigens in Tunisian patients.
Achour M; Kahla S; Zeghal D; Kochbati L; Mongi M; Zouari F; Oueslati R
Viral Immunol; 2009 Feb; 22(1):7-16. PubMed ID: 19210223
[TBL] [Abstract][Full Text] [Related]
4. Serological study in Tunisian cervical cancer patients.
Achour M; Kochbati L; Zeghal D; Kahla S; Maalej M; Zouari F; Oueslati R
Pathol Biol (Paris); 2009 Jul; 57(5):415-9. PubMed ID: 18586408
[TBL] [Abstract][Full Text] [Related]
5. A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection.
Monroy-García A; Gómez-Lim MA; Weiss-Steider B; la Rosa GP; Hernández-Montes J; Pérez-Saldaña K; Tapia-Guerrero YS; Toledo-Guzmán ME; Santiago-Osorio E; Sanchez-Peña HI; Mora-García Mde L
Virol J; 2011 Feb; 8():59. PubMed ID: 21306638
[TBL] [Abstract][Full Text] [Related]
6. Characterization of humoral immune responses against p16, p53, HPV16 E6 and HPV16 E7 in patients with HPV-associated cancers.
Reuschenbach M; Waterboer T; Wallin KL; Einenkel J; Dillner J; Hamsikova E; Eschenbach D; Zimmer H; Heilig B; Kopitz J; Pawlita M; Doeberitz Mv; Wentzensen N
Int J Cancer; 2008 Dec; 123(11):2626-31. PubMed ID: 18785210
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a multiplex immunoassay for the simultaneous quantification of type-specific IgG antibodies to E6/E7 oncoproteins of HPV16 and HPV18.
Layman H; Rickert KW; Wilson S; Aksyuk AA; Dunty JM; Natrakul D; Swaminathan N; DelNagro CJ
PLoS One; 2020; 15(3):e0229672. PubMed ID: 32214362
[TBL] [Abstract][Full Text] [Related]
8. Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer.
Jin Y; Choi JW; Kim HJ; Eddouzi J; Kim SC; Ju W; Kim YH; Kim HJ
Cancer Med; 2018 Nov; 7(11):5655-5664. PubMed ID: 30353680
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
[TBL] [Abstract][Full Text] [Related]
10. An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer.
de Vos van Steenwijk PJ; Heusinkveld M; Ramwadhdoebe TH; Löwik MJ; van der Hulst JM; Goedemans R; Piersma SJ; Kenter GG; van der Burg SH
Cancer Res; 2010 Apr; 70(7):2707-17. PubMed ID: 20233872
[TBL] [Abstract][Full Text] [Related]
11. Fusion protein vaccines targeting two tumor antigens generate synergistic anti-tumor effects.
Cheng WF; Chang MC; Sun WZ; Jen YW; Liao CW; Chen YY; Chen CA
PLoS One; 2013; 8(9):e71216. PubMed ID: 24058440
[TBL] [Abstract][Full Text] [Related]
12. Naive and radiolabeled antibodies to E6 and E7 HPV-16 oncoproteins show pronounced antitumor activity in experimental cervical cancer.
Phaëton R; Gutierrez J; Jiang Z; Karabakhtsian RG; Albanese J; Sunkara J; Fisher DR; Goldberg GL; Dadachova E
Immunotherapy; 2015; 7(6):631-40. PubMed ID: 26098137
[TBL] [Abstract][Full Text] [Related]
13. Antibodies against high-risk human papillomavirus proteins as markers for invasive cervical cancer.
Combes JD; Pawlita M; Waterboer T; Hammouda D; Rajkumar T; Vanhems P; Snijders P; Herrero R; Franceschi S; Clifford G
Int J Cancer; 2014 Nov; 135(10):2453-61. PubMed ID: 24729277
[TBL] [Abstract][Full Text] [Related]
14. Antigenic Peptide Prediction From E6 and E7 Oncoproteins of HPV Types 16 and 18 for Therapeutic Vaccine Design Using Immunoinformatics and MD Simulation Analysis.
Jabbar B; Rafique S; Salo-Ahen OMH; Ali A; Munir M; Idrees M; Mirza MU; Vanmeert M; Shah SZ; Jabbar I; Rana MA
Front Immunol; 2018; 9():3000. PubMed ID: 30619353
[TBL] [Abstract][Full Text] [Related]
15. Variations of human papillomavirus type 58 E6, E7, L1 genes and long control region in strains from women with cervical lesions in Liaoning province, China.
Liu JH; Lu ZT; Wang GL; Zhou WQ; Liu C; Yang LX; Sun ZR; Ruan Q
Infect Genet Evol; 2012 Oct; 12(7):1466-72. PubMed ID: 22659102
[TBL] [Abstract][Full Text] [Related]
16. Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts.
de Boer MA; Jordanova ES; van Poelgeest MI; van den Akker BE; van der Burg SH; Kenter GG; Fleuren GJ
Int J Cancer; 2007 Dec; 121(12):2711-5. PubMed ID: 17724722
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus 16-specific T-cell responses and spontaneous regression of anal high-grade squamous intraepithelial lesions.
Tong WW; Shepherd K; Garland S; Meagher A; Templeton DJ; Fairley CK; Jin F; Poynten IM; Zaunders J; Hillman RJ; Grulich AE; Kelleher AD; Carr A;
J Infect Dis; 2015 Feb; 211(3):405-15. PubMed ID: 25139018
[TBL] [Abstract][Full Text] [Related]
18. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16.
Hasan UA; Bates E; Takeshita F; Biliato A; Accardi R; Bouvard V; Mansour M; Vincent I; Gissmann L; Iftner T; Sideri M; Stubenrauch F; Tommasino M
J Immunol; 2007 Mar; 178(5):3186-97. PubMed ID: 17312167
[TBL] [Abstract][Full Text] [Related]
19. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
[TBL] [Abstract][Full Text] [Related]
20. T-cell response to human papillomavirus type 58 L1, E6, And E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer.
Chan PK; Liu SJ; Cheung TH; Yeo W; Ngai SM; Cheung JL; Chong P; Man S
Clin Vaccine Immunol; 2010 Sep; 17(9):1315-21. PubMed ID: 20668141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
